Overall rank by patents
#653
Across all tracked assignees
USPTO PatentsView assignee record - 686 granted patents across 125 technology areas, active 2015–2021. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C07C (ACYCLIC OR CARBOCYCLIC COMPOUNDS).
The verdict
Evonik holds 686 US patents across 125 technology areas, rank #653 of 50,000 tracked assignees.
Evonik Degussa Gmbh has been granted 686 US utility patents between 2015 and 2021, placing Evonik Degussa Gmbh at rank #653 across all assignees tracked by PlainPatent. This portfolio spans 125 distinct Cooperative Patent Classification (CPC) subclasses, averaging 15.6 claims per patent with primary concentration in C07C (ACYCLIC OR CARBOCYCLIC COMPOUNDS). As a Foreign Corporation, Evonik Degussa Gmbh is one of the broader-portfolio assignees in the PatentsView dataset. By volume, Evonik sits between Rivian IP Holdings, Llc (690 patents, rank #649) and Tianma Microelectronics Co., Ltd. (684 patents, rank #657) - the closest US assignees by grant volume. The composite Innovation Score of 56.9/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 23 grants, compared with 663 in the 2015–2019 window, a -97% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Evonik Degussa Gmbh's 15.6 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while a diversified footprint across 100+ CPC subclasses spreads risk across many technology fronts. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Evonik Degussa Gmbh against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Rivian IP Holdings, LLC
690 patents
Carl Zeiss Meditec AG
689 patents
SATURN LICENSING LLC
689 patents
The Research Foundation for The State University of New York
688 patents
EVONIK DEGUSSA GMBH
686 patents
GM Cruise Holdings LLC
685 patents
The Brigham and Women's Hospital, Inc.
685 patents
Yale University
685 patents
TIANMA MICROELECTRONICS CO., LTD.
684 patents
What this shows Evonik holds 686 patents at rank #653, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #653 in granted patent volume.
Other assignees with the most granted patents in Evonik's primary technology class.
Evonik's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
57 Top 6% higher than 94% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 118 | 17.2% |
| 2016 | 92 | 13.4% |
| 2017 | 142 | 20.7% |
| 2018 | 157 | 22.9% |
| 2019 | 154 | 22.4% |
| 2020 | 22 | 3.2% |
| 2021 | 1 | 0.1% |
Top 15 of 125 technology areas
Overall rank by patents
#653
Across all tracked assignees
56.9 out of 100
How to use this portfolio
Evonik's 686 grants land it in the top 6% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.